LEUCEMIA ACUTA MIELOIDE
- AC220-168. Phase 3, Double-Blind,, Placebo-Controlled Study of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Adult Patients with Newly Diagnosed FLT3-ITD (-) Acute Myeloid Leukemia
- AML1919 Ameliorate. A phase 3, prospective, multicenter intervention trial of early intensification in AML patients bearing FLT3 mutation based on peripheral blast clearance. A MYNERVA-GIMEMA study
- AML2420. A phase 2, prospective, multi-center intervention trial in patient with acute myeloid leukemia secondary to myeloproliferative neoplasm unfit for intensive chemotherapy investigating a treatment combination including decitabine and venetoclax – ENABLE (vENetoclax plus decitAbine treatment in Blastic phase of myeLoproliferative nEoplasms)
- ARO_013. Studio di fase III randomizzato, in doppio-cieco, placebo-controllato per ricerca sull’efficacia dell’aggiunta di crenolanib alla chemioterapia di salvataggio in comparazione con la terapia di salvataggio da sola in soggetti ≤ 75 anni di età affetti da leucemia mieloide acuta recidivante/refrattaria con mutazione FLT3
- AML-MRD-FLT3. Misurazione della Malattia misurabile residua (MRD) basata sulla presenza di FLT3-ITD misurata mediante tecnica “droplet digital PCR nelle Leucemie Mieloidi Acute (LMA). Studio prospettico e retrospettivo
- VenSafe. Studio osservazionale sulla correlazione tra l’esposizione al Venetoclax (concentrazione ematica e durata di trattamento) e la sua sicurezza (eventi avversi ematologici ed extraematologici) in pazienti affetti da Leucemia Mieloide Acuta
LEUCEMIA ACUTA LINFOBLASTICA
- GIMEMA: ALL2418. A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with positive Minimal Residual Disease before any Hematopoietic Stem Cell
- GIMEMA ALL2620. Ponatinib for the management of minimal residual disease (MRD) and hematologic relapse in adult Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients
- GIMEMA ALL2820. Newly diagnosed adult philadelphia Chromosome-positive lymphoblastic leukemia (Ph+ ALL). Sequential Treatment with Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy and Imatinib
- GIMEMA ALL2922. Combinazione di ponatinib e chemioterapia come trattamento di prima linea per i pazienti con leucemia acuta linfoblastica BCR/ABL1-like (LAL BCR/ABL1-like) – BALLik
- GIMEMA INO-FIRTS. Multicenter Retrospective observational study analyzing infective complications and the clinical outcome of patients with acute lymphoblastic leukemia treated with inotuzumab ozogamicin
SINDROMI MIELODISPLASTICHE
- AG946-C-002. A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Double-blind, Randomized,Placebo-Controlled (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes ( drug AG948)
- CA056-025. A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoietin-stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD) (drug luspatercept)
- CA056-1060. Phase 3b, open label study evaluating the efficacy and safety of luspatercept (BMS-986346/ACE-536) initiated at maximunx approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusion
- SY-1425-301. A Randomized, Double-blind, Placebo-controlled Phase 3 Study of SY-1425 plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome (drug Tamobaritene)